Neuroprotective strategies to prevent and treat Parkinson’s disease based on its pathophysiological mechanism
Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease after Alzheimer’s disease. PD exhibits clinical symptoms that include tremors, rigidity, and bradykinesia. Many drugs are available to treat PD, such as, l -dopa, COMT inhibitor, MAO-B inhibitor, and dopamine ag...
Saved in:
Published in | Archives of pharmacal research Vol. 40; no. 10; pp. 1117 - 1128 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Seoul
Pharmaceutical Society of Korea
01.10.2017
대한약학회 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Parkinson’s disease (PD) is the second most common progressive neurodegenerative disease after Alzheimer’s disease. PD exhibits clinical symptoms that include tremors, rigidity, and bradykinesia. Many drugs are available to treat PD, such as,
l
-dopa, COMT inhibitor, MAO-B inhibitor, and dopamine agonists, but these drugs simply compensate for dopamine loss in PD, and therefore, cannot completely suppress its symptoms or progression. Although the causes of PD are not clearly understood, common pathophysiological pathways, such as, oxidative stress, mitochondrial dysfunction, and neuroinflammation are considered to be etiological factors, and thus, many treatments and interventions have been developed to target these pathophysiological factors. This review describes the neuroprotective strategies devised based on current understanding of the pathophysiological mechanisms of PD. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
ISSN: | 0253-6269 1976-3786 1976-3786 |
DOI: | 10.1007/s12272-017-0960-8 |